SITE004-0080

SITE004 (DEU) › SITE004-0080

SITE004-0080

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2025-12-01

enrolled

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-12 (study day 129); relationship: not assessed

moderate assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-09 (study day 126); relationship: not assessed

mild assessed

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-06-14 (study day 9); relationship: NOT RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.